A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

NCT07227311 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Belantamab mafodotin
DRUG: Dexamethasone
DRUG: Pomalidomide
DRUG: Bortezomib
DRUG: Carfilzomib

Sponsor

GlaxoSmithKline